San Francisco, CA -- April 14, 2021 -- InvestorsHub
NewsWire -- Oncology Pharma Inc. (OTC:
ONPH) On April 7, 2021 Oncology Pharma, Inc. ( the "Company")
reported that it had been granted an exclusive worldwide license by
Regen BioPharma, Inc. to develop and commercialize pancreatic
cancer treatments utilizing Regen's proprietary intellectual
property pertaining to mRNA.
A Spokesperson for the Company, today expanded on the reasons
for obtaining this license stating:
"Pancreatic Cancer is one of the most lethal forms of cancer
ranking as the fourth leading cause of cancer deaths in the United
States. The median survival duration from diagnosis until death for
untreated advanced pancreatic cancer is approximately 3 1/2 months;
increasing to about eight months with treatment.
mRNA vaccines have become a promising platform for cancer
immunotherapy. The intellectual property which we licensed from
Regen encompasses an exciting method of utilizing mRNA to cause
changes in the cancer cells which would stimulate the patient's own
immune response to battle this deadly disease.
According to the National Cancer Institute more than 1.7 million
new cases of pancreatic cancer emerge in the United States per year
resulting in 609,604 deaths. The cost of treating pancreatic cancer
in the United States is $174 billion per year and growing. These
are staggering numbers.
We believe that developing a solid therapy to treat this disease
is our mission. We want to help save lives and bring hope where
currently little hope exists. We believe our mRNA based pancreatic
cancer therapies will prove dynamic and powerful."
The Spokesperson further noted "We are more than a biotechnology
company. We believe our shareholders expect us to not only develop
therapies that improve lives but to develop therapies that save
lives. Knowing what we know about pancreatic cancer, this is a
great cornerstone on which to focus our Company's research
activities."
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801 website: www.oncology-pharma.com
email: info@oncology-pharma.com